lorcaserin(856681-05-5)is an orally administered agent and a selective 5-ht2c receptor agonist for the treatment of obesity. it had been approved for marketing in us by fda on 27 june in 2012. in clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
fludarabine phosphate basic information |
product name: | fludarabine phosphate |
synonyms: | 2-fluoro-9-(5-o-phosphono-beta-d-arabinofuranosyl)-9h-purin-6-amin;2-fluoro-9-(5-o-phosphono-beta-d-arabinofuranosyl)-9h-purin-6-amine;2-fluoro-araamp;9-beta-arabinofuranosyl-2-fluoroadenine-5’-phosphate;9-beta-d-arabinofuranosyl-2-fluoroadenine5’-monophosphate;fludarabinemonophosphate;9-bata-d-arabinofuranosyl-2-fluoroadenine phosphate;9-beta-d-arabinofuranosyl-2-fluoroadenine-5'-dihydrogen phosphate |
cas: | 75607-67-9 |
mf: | c10h13fn5o7p |
mw: | 365.21 |
einecs: | |
product categories: | active pharmaceutical ingredients;antineoplastics;antineoplastic;api;anti-cancer&immunity;inhibitors |
mol file: | 75607-67-9.mol |